MedTrace Logo

Half-Dose Intracoronary Abciximab Bolus Improves the Mortality Outcome Compared to Standard Intravenous Regimen

NCT00320229 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2006-05-16

No results posted yet for this study

Summary

The aim of our study was to demonstrate that, during a percutaneous coronary intervention, even smaller amounts of abciximab than standard dose, injected locally, could achieve a rapid thrombus resolution and clinical improvement without concomitant differences in hemorrhagic complications

Conditions

Interventions

DRUG

abciximab

Sponsors & Collaborators

  • Cardiologia 2 - Emodinamica - Ospedale Maggiore, Novara, Italy

    collaborator UNKNOWN

  • Azienda Sanitaria Ospedaliera

    lead OTHER

Principal Investigators

  • Mara Sansa · Chief Interventional Cardiology - Ospedale Maggiore - Novara - Italy

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Completion
2005-07-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00320229 on ClinicalTrials.gov